Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)

13 de setembro de 2019 atualizado por: King's College London

A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

Visão geral do estudo

Descrição detalhada

Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).

Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.

Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.

Objectives:

  1. A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
  2. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

Tipo de estudo

Intervencional

Inscrição (Real)

42

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • England
      • London, England, Reino Unido, SE1 9NH
        • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

35 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).

REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.

WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

Exclusion Criteria:

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Intermittent Energy Restriction
Weight loss intervention: Intermittent Energy Restriction
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
Comparador Ativo: Continuous Energy Restriction
Weight loss intervention: Continuous Energy Restriction
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Revised QUICKI (RQUICKI)
Prazo: Baseline
Marker of insulin sensitivity
Baseline
RQUICKI
Prazo: day 29
Marker of insulin sensitivity
day 29
RQUICKI
Prazo: day 31
Marker of insulin sensitivity
day 31

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Peso corporal
Prazo: Linha de base
Linha de base
Circunferência da cintura
Prazo: Linha de base
Linha de base
Circunferência do quadril
Prazo: Linha de base
Linha de base
Concentração de glicose plasmática
Prazo: Linha de base
Jejum
Linha de base
Concentração plasmática de adiponectina
Prazo: Linha de base
Jejum
Linha de base
Concentração plasmática de leptina
Prazo: Linha de base
Jejum
Linha de base
Concentração plasmática de colesterol total
Prazo: Linha de base
Jejum
Linha de base
Concentração plasmática de colesterol de lipoproteína de baixa densidade (LDL)
Prazo: Linha de base
Jejum
Linha de base
Concentração plasmática de colesterol de lipoproteína de alta densidade (HDL)
Prazo: Linha de base
Jejum
Linha de base
Concentração plasmática de triglicerídeos
Prazo: Linha de base
Jejum
Linha de base
Colesterol total plasmático: proporção de colesterol HDL
Prazo: Linha de base
Jejum
Linha de base
Índice de massa corporal (IMC)
Prazo: Linha de base
Linha de base
Plasma glucose concentration
Prazo: day 29
Fasting
day 29
Plasma glucose concentration
Prazo: day 31
Fasting
day 31
Plasma insulin concentration
Prazo: Baseline
Fasting
Baseline
Plasma insulin concentration
Prazo: day 29
Fasting
day 29
Plasma insulin concentration
Prazo: day 31
Fasting
day 31
Plasma non-esterified fatty acid concentration
Prazo: Baseline
Fasting
Baseline
Plasma non-esterified fatty acid concentration
Prazo: day 29
Fasting
day 29
Plasma non-esterified fatty acid concentration
Prazo: day 31
Fasting
day 31
Plasma total cholesterol concentration
Prazo: day 29
Fasting
day 29
Plasma total cholesterol concentration
Prazo: day 31
Fasting
day 31
Plasma LDL cholesterol concentration
Prazo: day 29
Fasting
day 29
Plasma LDL cholesterol concentration
Prazo: day 31
Fasting
day 31
Plasma HDL cholesterol concentration
Prazo: day 29
Fasting
day 29
Plasma HDL cholesterol concentration
Prazo: day 31
Fasting
day 31
Plasma triglyceride concentration
Prazo: day 29
Fasting
day 29
Plasma triglyceride concentration
Prazo: day 31
Fasting
day 31
Plasma total cholesterol:HDL cholesterol ratio
Prazo: day 29
Fasting
day 29
Plasma total cholesterol:HDL cholesterol ratio
Prazo: day 31
Fasting
day 31
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Prazo: Baseline
Fasting (calculated from insulin and glucose)
Baseline
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Prazo: day 29
Fasting (calculated from insulin and glucose)
day 29
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Prazo: day 31
Fasting (calculated from insulin and glucose)
day 31
Plasma adiponectin concentration
Prazo: day 29
Fasting
day 29
Plasma adiponectin concentration
Prazo: day 31
Fasting
day 31
Plasma leptin concentration
Prazo: day 29
Fasting
day 29
Plasma leptin concentration
Prazo: day 31
Fasting
day 31
Plasma interleukin-6 concentration
Prazo: Baseline
Fasting
Baseline
Plasma interleukin-6 concentration
Prazo: day 29
Fasting
day 29
Plasma interleukin-6 concentration
Prazo: day 31
Fasting
day 31
Plasma beta-hydroxybutyrate concentration
Prazo: Baseline
Fasting
Baseline
Plasma beta-hydroxybutyrate concentration
Prazo: day 29
Fasting
day 29
Plasma beta-hydroxybutyrate concentration
Prazo: day 31
Fasting
day 31
Plasma norepinephrine concentration
Prazo: Baseline
Fasting
Baseline
Plasma norepinephrine concentration
Prazo: day 29
Fasting
day 29
Plasma norepinephrine concentration
Prazo: day 31
Fasting
day 31
Plasma soluble alpha-klotho concentration
Prazo: Baseline
Fasting
Baseline
Plasma soluble alpha-klotho concentration
Prazo: day 29
Fasting
day 29
Plasma soluble alpha-klotho concentration
Prazo: day 31
Fasting
day 31
Body weight
Prazo: day 29
day 29
Body weight
Prazo: day 31
day 31
BMI
Prazo: day 29
day 29
BMI
Prazo: day 31
day 31
Waist circumference
Prazo: day 29
day 29
Waist circumference
Prazo: day 31
day 31
Hip circumference
Prazo: day 29
day 29
Hip circumference
Prazo: day 31
day 31
Percentage body fat
Prazo: Baseline
Baseline
Percentage body fat
Prazo: day 29
day 29
Percentage body fat
Prazo: day 31
day 31
Percentage lean body mass
Prazo: Baseline
Baseline
Percentage lean body mass
Prazo: day 29
day 29
Percentage lean body mass
Prazo: day 31
day 31
Heart rate variability (resting)
Prazo: Baseline
supine
Baseline
Heart rate variability (resting)
Prazo: day 29
supine
day 29
Heart rate variability (resting)
Prazo: day 31
supine
day 31
Heart rate variability (ambulatory)
Prazo: 24 h recording at baseline
24 h recording at baseline
Heart rate variability (ambulatory)
Prazo: 24 h recording on day 29
24 h recording on day 29
Heart rate variability (ambulatory)
Prazo: 24 h recording on day 31
24 h recording on day 31
Heart rate variability (sleep-time)
Prazo: Baseline
Baseline
Heart rate variability (sleep-time)
Prazo: day 29
day 29
Heart rate variability (sleep-time)
Prazo: day 31
day 31
Heart rate variability (during mental stress)
Prazo: Baseline
Baseline
Heart rate variability (during mental stress)
Prazo: day 29
day 29
Heart rate variability (during mental stress)
Prazo: day 31
day 31
Ambulatory blood pressure 24 h
Prazo: 24 h analysis at baseline
24 h analysis at baseline
Ambulatory blood pressure daytime
Prazo: Daytime analysis at baseline
Daytime analysis at baseline
Ambulatory blood pressure night-time
Prazo: Night-time analysis at baseline
Night-time analysis at baseline
Ambulatory blood pressure 24 h
Prazo: 24 h analysis on day 29
24 h analysis on day 29
Ambulatory blood pressure daytime
Prazo: daytime analysis on day 29
daytime analysis on day 29
Ambulatory blood pressure night-time
Prazo: night-time analysis on day 29
night-time analysis on day 29
Ambulatory blood pressure 24 h
Prazo: 24 h analysis on day 31
24 h
24 h analysis on day 31
Ambulatory blood pressure daytime
Prazo: Daytime analysis on day 31
day time
Daytime analysis on day 31
Ambulatory blood pressure night-time
Prazo: Night-time analysis on day 31
night-time
Night-time analysis on day 31
Digital volume pulse - stiffness index (SI)
Prazo: Baseline
Stiffness index
Baseline
Digital volume pulse - SI
Prazo: day 29
Stiffness index
day 29
Digital volume pulse - SI
Prazo: day 31
Stiffness index
day 31
Digital volume pulse - reflection index (RI)
Prazo: Baseline
reflection index
Baseline
Digital volume pulse - RI
Prazo: day 29
reflection index
day 29
Digital volume pulse - RI
Prazo: day 31
reflection index
day 31
Mnemonic Similarity Test
Prazo: Baseline
Baseline
Mnemonic Similarity Test
Prazo: day 29
day 29
Mnemonic Similarity Test
Prazo: day 31
day 31
Power of food scale
Prazo: Baseline
questionnaire
Baseline
Power of food scale
Prazo: day 29
questionnaire
day 29
Power of food scale
Prazo: day 31
questionnaire
day 31
COPE (not an acronym)
Prazo: Baseline
questionnaire
Baseline
COPE
Prazo: day 29
questionnaire
day 29
COPE
Prazo: day 31
questionnaire
day 31

Outras medidas de resultado

Medida de resultado
Prazo
Adverse events
Prazo: Baseline until endpoint: day 31 (+/-1 day)
Baseline until endpoint: day 31 (+/-1 day)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de fevereiro de 2016

Conclusão Primária (Real)

1 de julho de 2016

Conclusão do estudo (Real)

1 de julho de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

22 de janeiro de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de fevereiro de 2016

Primeira postagem (Estimativa)

11 de fevereiro de 2016

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de setembro de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de setembro de 2019

Última verificação

1 de julho de 2016

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever